SETD2 and nonpapillary renal cell carcinoma: They also demonstrated that TGX221-treated VHL and SETD2 deficient ccRCC-derived cell lines have a significantly reduced migrating and invading capacity when compared to VHL deficient ccRCC-derived cell lines, suggesting a novel molecular connection between PI3Kβ and SETD2.